Narcolepsy Market Research Report present a detailed analysis of the market listing Narcolepsy Epidemiology, Drug therapies and pipeline for study period from 2016-2027.

Narcolepsy Market Insight, Epidemiology and Market Forecast 2027

DelveInsight's 'Narcolepsy - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical &amp; forecasted epidemiology as well as the market trends of Narcolepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Narcolepsy from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
<h2>Geography Covered</h2>
&bull; The United States
&bull; EU5 (Germany, France, Italy, Spain and the United Kingdom)
&bull; Japan
<h2>Study Period: 2016-2027</h2>
<h2>Narcolepsy - Disease Understanding and Treatment Algorithm</h2>
The DelveInsight Narcolepsy market report gives the thorough understanding of the Narcolepsy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Narcolepsy in the US, Europe, and Japan.
<h2>Narcolepsy Epidemiology</h2>
The Narcolepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, narcolepsy with and without cataplexy prevalent cases, prevalent cases by manifestations, diagnosed cases, age-specific diagnosed cases) scenario of Narcolepsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, total prevalent population of Narcolepsy in 7 major markets are about 507,138 in 2016.
<h2>Narcolepsy Drug Chapters</h2>
This segment of the Narcolepsy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
<h2>Narcolepsy Market Outlook</h2>
The Narcolepsy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Narcolepsy in 7MM was found to be USD 1,262 Million in 2016, and is expected to increase from 2016-2027.
<h2>Narcolepsy Drugs Uptake</h2>
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
<h2>Narcolepsy Report Insights</h2>
&bull; Patient Population
&bull; Therapeutic Approaches
&bull; Pipeline Analysis
&bull; Market Size and Trends
&bull; Market Opportunities
&bull; Impact of upcoming Therapies
&nbsp;
<h2>Narcolepsy Report Key Strengths</h2>
&bull; 10 Year Forecast
&bull; 7MM Coverage
&bull; Epidemiology Segmentation
&bull; Drugs Uptake
&bull; Highly Analyzed Market
&bull; Key Cross Competition
<h2>Narcolepsy Report Assessment</h2>
&bull; Current Treatment Practices
&bull; Unmet Needs
&bull; Detailed Pipeline Product Profiles
&bull; Market Attractiveness
&bull; Market Drivers and Barriers
<h2>Key Benefits</h2>
&bull; This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Narcolepsy market
&bull; Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy market
&bull; To understand the future market competition in the Narcolepsy market.

1. Key Insights2. Narcolepsy Market Overview at a Glance2.1. Market Share (%) Distribution of Narcolepsy in 20172.2. Market Share (%) Distribution of Narcolepsy in 20273. Disease Background and Overview: Narcolepsy3.1. Introduction3.2. Signs and Symptoms3.3. Complications3.4. Pathophysiology3.5. Etiology3.6. Risk Factors3.7. Diagnosis3.8. Treatment4. Epidemiology and Patient Population4.1. Key Findings4.2. Population and Forecast Parameters5. 7MM Total Prevalent Patient Population of Narcolepsy5.1. United States5.1.1. Prevalent Patient Population of Narcolepsy in the United States5.1.2. Narcolepsy with and without Cataplexy Cases5.1.3. Prevalent Cases by Clinical Manifestation5.1.4. Diagnosed Cases of Narcolepsy5.1.5. Age-Specific Diagnosed Cases of Narcolepsy5.2. Germany5.2.1. Prevalent Population of Narcolepsy5.2.2. Narcolepsy cases with and without Cataplexy5.2.3. Prevalent Cases by Clinical Manifestation5.2.4. Diagnosed Cases of Narcolepsy5.2.5. Age-Specific Diagnosed Cases of Narcolepsy5.3. France5.3.1. Prevalent Population of Narcolepsy5.3.2. Narcolepsy cases with and without Cataplexy5.3.3. Prevalent Cases by Clinical Manifestation5.3.4. Diagnosed Cases of Narcolepsy5.3.5. Age-Specific Diagnosed Cases of Narcolepsy5.4. Italy5.4.1. Prevalent Population of Narcolepsy in Italy5.4.2. Narcolepsy cases with and without Cataplexy5.4.3. Prevalent Cases by Clinical Manifestation5.4.4. Diagnosed Cases of Narcolepsy5.4.5. Age-Specific Diagnosed Cases of Narcolepsy5.5. Spain5.5.1. Prevalent Population of Narcolepsy5.5.2. Narcolepsy cases with and without Cataplexy5.5.3. Prevalent Cases by Clinical Manifestation5.5.4. Diagnosed Cases of Narcolepsy5.5.5. Age-Specific Diagnosed Cases of Narcolepsy5.6. United Kingdom5.6.1. Prevalent Cases of Narcolepsy5.6.2. Narcolepsy cases with and without Cataplexy5.6.3. Prevalent Cases by Clinical Manifestation5.6.4. Diagnosed Cases of Narcolepsy5.6.5. Age-Specific Diagnosed Cases of Narcolepsy5.7. Japan5.8. Prevalent Population of Narcolepsy5.9. Narcolepsy cases with and without Cataplexy5.10. Prevalent Cases by Clinical Manifestation5.11. Diagnosed Cases of Narcolepsy5.12. Age-Specific Diagnosed Cases of Narcolepsy6. Current Treatment and Medical Practices6.1. Treatment Algorithm6.2. Guideline and management7. Unmet Needs8. Marketed drugs8.1. PROVIGIL8.1.1. Drug Description8.1.2. Regulatory Milestones8.1.3. Advantages &amp; Disadvantages8.1.4. Product Profile8.2. XYREM8.2.1. Description8.2.2. Regulatory Milestones8.2.3. Advantages and Disadvantages8.2.4. Product Profile9. Other Narcoleptics9.1. Anafranil (clomipramine)9.1.1. Description9.1.2. Regulatory Milestones9.1.3. Advantages and Disadvantages9.1.4. Product Profile9.2. Desipramine9.2.1. Description9.2.2. Regulatory Milestones9.2.3. Advantages and Disadvantages9.2.4. Product Profile9.3. Prozac (Fluoxetine)9.3.1. Description9.3.2. Regulatory Milestones9.3.3. Advantages and Disadvantages9.3.4. Product Profile9.4. Tofranil (Imipramine)9.4.1. Description9.4.2. Advantages and Disadvantages9.4.3. Product Profile9.5. Vivactil (Protriptyline)9.5.1. Description9.5.2. Regulatory Milestones9.5.3. Advantages and Disadvantages9.5.4. Product Profile9.6. Zoloft (Sertraline)9.6.1. Description9.6.2. Regulatory Milestones9.6.3. Advantages and Disadvantages9.6.4. Product Profile9.7. Effexor (Venlafaxine)9.7.1. Description9.7.2. Regulatory Milestones9.7.3. Advantages and Disadvantages9.7.4. Product Profile9.8. Desoxyn (Methamphetamine)9.8.1. Description9.8.2. Regulatory Milestones9.8.3. Advantages and Disadvantages9.8.4. Product Profile9.9. NUVIGIL9.9.1. Description9.9.2. Regulatory Milestones9.9.3. Advantages and Disadvantages9.9.4. Product Profile9.10. Wakix (Pitolisant)9.10.1. Description9.10.2. Regulatory Milestones9.10.3. Advantages and Disadvantages9.10.4. Product Profile9.11. Ritalin9.11.1. Description9.11.2. Regulatory Milestones9.11.3. Advantages and Disadvantages9.11.4. Product Profile9.12. Dexedrine9.12.1. Description9.12.2. Regulatory Milestones9.12.3. Advantages and Disadvantages9.12.4. Product Profile9.13. Adderall9.13.1. Description9.13.2. Regulatory Milestones9.13.3. Advantages and Disadvantages9.13.4. Product Profile9.14. Atomoxetine9.14.1. Description9.14.2. Regulatory Milestones:9.14.3. Advantages and Disadvantages9.14.4. Product Profile10. Emerging Drugs10.1. Xyrem: Jazz Pharmaceuticals10.1.1. Regulatory Milestones10.1.2. Clinical Development10.1.3. Clinical Trial Information10.1.4. Product Profile10.2. Mazindol CR: NLS Pharma10.2.1. Product Description10.2.2. Product Development Activities10.2.3. Product Profile10.3. JZP-258: Jazz Pharmaceuticals Inc10.3.1. Drug Description10.3.2. Regulatory Milestones10.3.3. Clinical Development10.3.4. Product Profile10.4. JZP-110: Jazz Pharmaceuticals10.4.1. Drug Description10.4.2. Regulatory Milestones10.4.3. Pre-Clinical Development10.4.4. Clinical Development10.4.5. Safety and Efficacy10.4.6. Product Profile10.5. Sodium oxybate ER: Avadel Pharmaceuticals10.5.1. Product Description10.5.2. Regulatory Milestones10.5.3. Clinical Developments10.5.4. Product Profile10.6. TS-091: Taisho Pharmaceutical Co10.6.1. Clinical Development10.6.2. Clinical Trial Information10.6.3. Product Profile10.7. BTD - 001: Balance Therapeutics10.7.1. Clinical Development10.7.2. Clinical Trial Information10.7.3. Product Profile10.8. Pitolisant: Bioprojet10.8.1. Regulatory Milestones10.8.2. Other Clinical Activities10.8.3. Clinical Development10.8.4. Clinical Trial Information10.8.5. Product Profile10.9. THN102 (Modafinil + Flecainide): Theranexus10.9.1. Regulatory Milestones10.9.2. Clinical Development10.9.3. Clinical Trial Information10.9.4. Product Profile11. Narcolepsy: 7 Major Market Analysis12. Narcolepsy: 7 Major Market Outlook13. Market Size of Narcolepsy in 7MM14. Market Outlook by Country14.1. The United States: Market Outlook14.1.1. Total Market size of Narcolepsy in the U.S.14.1.2. Therapy-based market size of Narcolepsy in the U.S.14.2. EU-5 Countries: Market Outlook14.2.1. Germany14.2.2. Total Market size of Narcolepsy in Germany14.2.3. Therapy-based market size of Narcolepsy in Germany14.2.4. France14.2.5. Total Market size of Narcolepsy in France14.2.6. Therapy-based market size of Narcolepsy in France14.2.7. United Kingdom14.2.8. Total Market size of Narcolepsy in the UK14.2.9. Therapy-based market size of Narcolepsy in the UK14.2.10. Spain14.2.11. Total Market size of Narcolepsy in Spain14.2.12. Therapy-based market size of Narcolepsy in Spain14.2.13. Italy14.2.14. Total Market size of Narcolepsy in Italy14.2.15. Therapy-based market size of Narcolepsy in Italy14.3. Japan14.3.1. Market Outlook14.3.2. Total Market size of Narcolepsy in Japan14.3.3. Therapy-based market size of Narcolepsy in Japan15. Market Drivers16. Market Barriers17. Appendix18. Report Methodology18.1. Sources Used19. DelveInsight Capabilities20. Disclaimer21. About DelveInsight

Narcolepsy- Market Insight, Epidemiology and Market Forecast - 2027

Narcolepsy- Market report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Narcolepsy in the 7MM